数量结构-活动关系
鉴定(生物学)
化学
虚拟筛选
药物发现
结肠腺癌
计算机科学
合理设计
随机森林
系统药理学
机器学习
计算生物学
药物开发
化学
药品
特征选择
公共化学
系统生物学
可药性
信号转导
药物设计
癌变
生物网络
深度学习
结直肠癌
PI3K/AKT/mTOR通路
瑞戈非尼
特征(语言学)
生物
作者
Divya Sharma,Sivakumar Arumugam
标识
DOI:10.1016/j.compbiomed.2025.111068
摘要
The dysregulation of the Wnt/β-catenin signaling pathway serves as a central driver of Colorectal cancer (CRC) initiation and progression. Tankyrase (TNKS), a PARP family enzyme, facilitates Wnt-driven tumorigenesis by PARylating and destabilizing Axin, thereby promoting β-catenin accumulation. In APC-mutated CRC, TNKS inhibition restores β-catenin degradation, highlighting its potential as a therapeutic target. To address this gap, an integrative QSAR model was constructed to identify novel TNKS inhibitors with favorable pharmacokinetic and therapeutic efficacy. A dataset of 1100 TNKS inhibitors was retrieved from the ChEMBL database and subjected to ligand-based QSAR modeling to predict potent chemical scaffolds based on 2D and 3D structural and physicochemical molecular descriptors. To enhance model reliability, Machine learning (ML) approaches such as feature selection and random forest (RF) classification models were applied. The models were trained, optimized, and rigorously validated using internal (cross-validation) and external test sets, achieving a high predictive performance (ROC-AUC) of 0.98. Virtual screening of prioritized candidates was complemented by molecular docking, dynamic simulation, and principal component analysis to evaluate binding affinity, complex stability, and conformational landscapes. This strategy led to the identification of a potential TNKS inhibitor, Q1 (Olaparib), as a possible repurposed drug against TNKS. Network pharmacology further contextualized TNKS within CRC biology, mapping disease-gene interactions and functional enrichment to uncover TNKS-associated roles in oncogenic pathways. Collectively, these findings underscore the effectiveness of combining machine learning and system biology to accelerate rational drug discovery. Olaparib emerges as a promising candidate for TNKS-targeted therapy, providing a strong computational foundation for experimental validation and future preclinical drug development.
科研通智能强力驱动
Strongly Powered by AbleSci AI